<DOC>
	<DOCNO>NCT01501266</DOCNO>
	<brief_summary>The purpose study confirm safety profile frequency serious adverse event unexpected adverse event overall efficacy Faslodex long term treatment daily clinical practice .</brief_summary>
	<brief_title>Faslodex Specific Clinical Experience Investigation</brief_title>
	<detailed_description>MC MD</detailed_description>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Patients treat Faslodex first time due postmenopausal breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>postmenopausal breast cancer</keyword>
	<keyword>Faslodex</keyword>
	<keyword>cohort</keyword>
</DOC>